新生儿肺内型与肺外型ARDS中肺动脉压及心功能监测的意义
本研究为观察性研究,纳入2016年1月至2020年12月东南大学医学院附属盐城医院新生儿科收治的128例ARDS新生儿,其中ARDSp组67例、ARDSexp组61例。机械通气开始后比较两组氧合指数、肺动脉压、心功能参数及NT-proBNP,并记录肺动脉高压发生率。结果显示ARDSp组PAH发生率、OI、PAP、NT-proBNP及RV-Tei均显著高于ARDSexp组,PAP与NT-proBNP呈显著正相关。米力农治疗中重度PAH后两组PAP及RV-Tei均呈下降趋势,ARDSexp组72小时下降更显著;ARDSp组机械通气时间及住院总时间更长,28天累积生存率更低。
要点
- 新生儿ARDS中ARDSp组PAH发生率97.01%,显著高于ARDSexp组的70.49%(P<0.01)。
- PAP与NT-proBNP呈显著正相关(r=0.918,P<0.01),动态监测PAP可反映右心负荷。
- 米力农治疗中重度PAH时,ARDSexp组72小时PAP(38.42±8.95 mmHg)及RV-Tei(0.58±0.19)下降较ARDSp组更显著。
- ARDSp组机械通气时间(10.12±1.36天)及住院总时间(16.52±3.25天)显著长于ARDSexp组,28天累积生存率更低(82.09% vs. 95.01%)。
适用人群与场景
- 纳入2016年1月至2020年12月东南大学医学院附属盐城医院新生儿科收治的128例ARDS新生儿,其中ARDSp组67例、ARDSexp组61例。
- 排除标准原文未提及。
诊断标准与关键阈值
- PAH诊断标准:肺动脉收缩压(PASP)>35 mmHg或超过体循环收缩压的2/3。
- PAH严重度分级:PASP 50-69 mmHg为中度,PASP≥70 mmHg为重度。
- 氧合指数(OI)计算公式:OI=平均气道压(Pmean)×吸入氧浓度(FiO2)/动脉血氧分压(PaO2)×100。
处置流程与药物剂量
- 机械通气开始后监测OI、PAP、心功能参数(CI、LVEF、RV-Tei)及血浆NT-proBNP。
- 对合并中重度PAH(PASP 50-69 mmHg为中度,≥70 mmHg为重度)的新生儿使用米力农治疗,原文未提及具体剂量、给药途径及频次。
- 米力农治疗期间动态观察PAP和RV-Tei变化,原文未提及目标值或停药阈值。
红旗征与不能漏的情况
- 新生儿ARDS出现中重度PAH(PASP 50-69 mmHg为中度,≥70 mmHg为重度)提示病情重,需针对性干预。
- ARDSp组PAH发生率高达97.01%,28天累积生存率显著低于ARDSexp组(82.09% vs. 95.01%),需警惕不良预后。
研究设计与关键结果
- 研究类型:观察性研究;样本量128例,单中心(东南大学医学院附属盐城医院新生儿科);人群为ARDS新生儿,ARDSp组67例、ARDSexp组61例。
- PAP与NT-proBNP显著正相关(r=0.918,P<0.01)。
- 中重度PAH患儿共97例(ARDSp组63例、ARDSexp组34例),米力农治疗后两组PAP及RV-Tei均下降,ARDSexp组72小时PAP(38.42±8.95 mmHg vs. 45.67±13.32 mmHg)及RV-Tei(0.58±0.19 vs. 0.61±0.13)下降更显著(均P<0.05);拔管前两组PAP及RV-Tei无显著差异。
- ARDSp组机械通气时间(10.12±1.36天 vs. 6.31±1.31天)及住院总时间(16.52±3.25天 vs. 13.12±3.57天)显著长于ARDSexp组(均P<0.01);28天累积生存率ARDSp组82.09% vs. ARDSexp组95.01%(Log-Rank χ2=5.062,P=0.025)。
证据类型、等级与局限
- 证据类型:单中心观察性研究;原文未提及证据等级或推荐强度。
- 局限:单中心、观察性设计、样本量128例;原文未提及盲法或随机化。
对床旁实践的改变
- 对新生儿ARDS应动态监测PAP和RV-Tei以评估病情严重度,肺内型ARDS需更警惕PAH及不良预后。
- 合并中重度PAH的新生儿可考虑米力农治疗以降低PAP、改善右心功能,但原文未提供剂量方案,不能直接作为用药推荐。
- PAP与NT-proBNP显著相关,NT-proBNP可作为无创辅助监测指标。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the dynamic changes of pulmonary arterial pressure (PAP) and cardiac function in neonates with pulmonary or extra-pulmonary acute respiratory distress syndrome (ARDSp/ARDSexp).
METHODS: An observational study was conducted. A total of 128 neonates with ARDS admitted to neonatology department of the Affiliated Yancheng Hospital of Southeast University Medical College from January 2016 to December 2020 were enrolled, with 67 neonates in ARDSp group and 61 neonates in ARDSexp group. After starting mechanical ventilation, oxygenation index [OI, OI = mean airway pressure (Pmean)×fraction of inspired oxygen (FiO2)/arterial partial pressure of oxygen (PaO2)×100], PAP, cardiac function parameters [cardiac index (CI), left ventricular ejection fraction (LVEF), right ventricular Tei (RV-Tei)], and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) were compared between the two groups; the incidence of pulmonary arterial hypertension [PAH, pulmonary artery systolic pressure (PASP) was more than 35 mmHg (1 mmHg = 0.133 kPa) or more than 2/3 of the systolic blood pressure of the body circulation] of neonates was recorded. The correlation between PAP and NT-proBNP was analyzed by Pearson correlation method. The dynamically changes in PAP and RV-Tei before and after using Milrinone in neonates with ARDSp and ARDSexp combined with moderate-severe PAH (PASP 50-69 mmHg was moderate, and PASP ≥ 70 mmHg was severe) were observed. The duration of mechanical ventilation, total length of hospital stay and prognosis were recorded; Kaplan-Meier survival curve was drawn to analyze the 28-day survival of the two groups.
RESULTS: The occurrence rate of PAH in ARDSp group was significantly higher than that in ARDSexp group (97.01% vs. 70.49%, P < 0.01). OI, PAP, NT-proBNP and RV-Tei were also higher [OI: 17.61±6.12 vs. 11.04±5.35, PAP (mmHg): 64.27±9.54 vs. 53.61±6.47, NT-proBNP (ng/L): 23 126.32±1 485.14 vs. 18 624.24±1 647.15, RV-Tei: 0.61±0.22 vs. 0.52±0.19, all P < 0.05], but there was no significant difference in CI or LVEF between the two groups. Pearson correlation analysis showed that PAP was significantly positively correlated with NT-proBNP (r = 0.918, P < 0.01). There were 97 ARDS neonates with moderate-severe PAH with 63 in ARDSp group and 34 in ARDSexp group. Both PAP and RV-Tei in the two group showed a decreasing trend with the prolongation of Milrinone treatment, the decrease was more significant in the ARDSexp group compared with ARDSp group, the difference was statistically significant at 72 hours of treatment [PAP (mmHg): 38.42±8.95 vs. 45.67±13.32, RV-Tei: 0.58±0.19 vs. 0.61±0.13, both P < 0.05]; there was no significant difference in PAP or RV-Tei before extubation between the two groups. The duration of mechanical ventilation and the total length of hospital stay in ARDSp group were significantly longer than those in ARDSexp group [duration of mechanical ventilation (days): 10.12±1.36 vs. 6.31±1.31, total length of hospital stay (days): 16.52±3.25 vs. 13.12±3.57, both P < 0.01]. Kaplan-Meier survival curve showed that neonate in ARDSp group had a significantly lower 28-day cumulative survival rate as compared with ARDSexp group (82.09% vs. 95.01%; Log-Rank test: χ2 = 5.062, P = 0.025).
CONCLUSIONS: Both PAP and RV-Tei were significantly increased in neonates with ARDS, PAP in neonates with ARDSp were significantly higher than that in neonates with ARDSexp. Dynamic monitoring of PAP and RV-Tei can reflect the severity of ARDS in neonates, and targeted intervention of pulmonary surfactant combined with Milinone for improving oxygenation and reducing PAP is one of the effective methods for the treatment of PAH.
参考来源
- Yin T, Hu Y, Cheng S, et al. [Significance of monitoring pulmonary arterial pressure and cardiac function in neonates with pulmonary or extra-pulmonary acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34412754. doi:10.3760/cma.j.cn121430-20210222-00702
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。